More than 100 years at the forefront of pharmaceutical innovation

Daiichi Sankyo is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets.

While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia and bacterial infections, Daiichi Sankyo is also engaged in the development of treatments for thrombotic disorders and focuses on the discovery of novel oncology and cardiovascular-metabolic therapies.

The company's roots extend back to 1899 and the early days of industrialisation of the pharmaceutical sector. The company was created in 2005 through the merger of two traditional Japanese enterprises, Daiichi and Sankyo. Daiichi Sankyo's world headquarters are in Tokyo, Japan, and its European base is located in Munich, Germany.

The company does business in nearly 60 countries around the world. Daiichi Sankyo has been one of the strongest Japanese pharmaceutical companies in- and outside Japan. With net sales of nearly $10,238 million in fiscal year 2010 (as of 31 March 2011), Daiichi Sankyo is one of the world's 20 leading pharmaceutical companies.

Daiichi Sankyo employs almost 30,500 people, who passionately work to achieve the company's goals. In delivering high-quality products, services and processes, precision serves as another cornerstone of the company's philosophy.

Daiichi Sankyo is dynamically moving ahead with efforts to overcome challenges associated with unmet medical needs.
While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, Daiichi Sankyo is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies.

Learn more about the Daiichi Sankyo global research and development activities and our activities in Japan, Europe and US.